StockNews.com started coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Free Report) in a report published on Tuesday morning. The firm issued a sell rating on the biopharmaceutical company’s ...

Minerva Neurosciences Inc. (NASDAQ:NERV) stock has reached a new 52-week low, trading at $2.03, as investors show concern ...

Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company with a current market capitalization of $15.21 million, has received a conditional extension to remain listed ...

Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company with a current market capitalization of $15.21 million, has received a conditional extension to remain listed on ...

Investors in Minerva Neurosciences, Inc. (NASDAQ:NERV) need to pay close attention to the stock based on moves in the options market lately. That is because the Jun 19, 2020 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

KZR Kezar Life Sciences, Inc.

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

And Cobenfy's approval comes after two other recent setbacks in the late-stage schizophrenia pipeline; namely, the FDA’s rejection of Minerva Neurosciences’ application for roluperidone and ...